Clinical trial management services firm Clario, formerly ERT and Bioclinca, has expanded its partnership with Chinese radiopharmaceutical manufacturer and PET contrast research organization XingImaging.
The firms previously collaborated in 2018 to support multicenter clinical trials requiring PET for eligibility and drug efficacy evaluation. In an expanded partnership, the companies will now team up to expedite clinical trials and drug discovery in China for targets such as amyloid, tau, and others, according to Clario and XingImaging.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
